Oxford-BMS Fellowship
This prestigious 3-year Fellowship (formerly Oxford-Celgene Fellowship) aims to stimulate new scientific discovery and translation and to facilitate skills and people transfer between researchers in academia and industry.
Bristol Myers Squibb (BMS) is a global biopharmaceutical company making advancements in oncology, haematology, immunology and cardiovascular disease. BMS are dedicated to helping patients prevail over serious diseases through a diverse and promising pipeline and new scientific platforms.
BMS acquired Celgene in 2019. Prior to 2019, in partnership with the Oxford Medical Sciences Division, Celgene co-developed and provided support for fellowships which will continue as the Oxford-BMS Translational Research Fellowship Programme.
The goals of this scheme are to stimulate new scientific discovery and translation and to facilitate skills and people transfer between researchers in academia and industry.
This programme offers fellows an opportunity to gain exposure to the field of commercial drug discovery and development. Fellows will have an assigned company mentor and where appropriate be encouraged to spend some time based in BMS laboratories.
Funding will be awarded to Oxford Principal Investigators to support 3 year fellowship projects for early career researchers that demonstrate a clear translational value to the advancement of therapeutics. Three to four awards are made annually.
Currently there are 22 fellows working with BMS and you can read about their projects here.
Principle Investigators should apply for fellowship funding to support clinical (Grade E64) or basic research scientists (Grade 7/8) committed to translational science and interested in obtaining experience with drug development in an industrial setting.
Fellowship applications may include a named fellow, but this is not mandatory. It is expected that a suitable fellowship candidate will be identified by the Principle Investigator within 6 months of notification of successful project selection.
Prospective Principle Investigator applicants should read the application guidance which can be downloaded here.
17th February 5pm - Deadline for pre-applications to secure a 1:1 meeting with BMS
12th March - 1:1 Meetings with BMS scientists to discuss pre-application project ideas
2nd April 5pm - Deadline for full proposal (submitted through IRAMS)
Early June - Panel review meeting
Late June - Decisions to applicants
Projects with named fellows - expected start dates from 01 October 2020
Projects without named fellows - expected start dates from 01 January 2021
For all enquiries please contact Charlotte Bell, Industry Partnerships Manager, Medical Sciences Industry Partnerships Office
Email: charlotte.bell@medsci.ox.ac.uk
If you would like to book a 1:1 to discuss you potential application with BMS on Thursday 12th March 2020, please complete the pre-application questions and email to charlotte.bell@medsci.ox.ac.uk before 5pm on Monday 17th February.
JOINT STEERING COMMITTEE
Professor Sir Marc Feldmann (Oxford)
Professor Fiona Powrie (Oxford)
Professor Chas Bountra (Oxford)
Dr. Maxine Allen (Oxford)
Dr. Rupert Vessey (Celgene)
Leon Carayannopoulos (Celgene)
James Carmichael (Celgene)
Current Fellows
|
|
|
|
'Inhibition of alpha-synuclein aggregation and glial activation as a therapeutic strategy for Parkinson’s disease' |
'A computational framework for T cell trafficking and dynamics in anti-tumour immune responses' |
'Studying the effects of citrullination on the dynamics of receptor-ligand pair interactions at the Immune Synapse' |
|
PI: Richard Wade-Martins |
PI: Mark Coles, Eamonn Gaffney |
|
|
|
|
|
'Investigation of epigenetic and post-translational modifications in altered STAT3' |
'Protein kinase C-θ and PD-1 as a therapeutic target in inflammatory arthritis' |
'Combination therapy of low dose regulatory T cells and low dose IL-2 to prevent rejection in transplantation' |
|
PI: Professor Holm Uhlig & Dr. Arian Laurence |
PI: Graham Ogg, Peter Taylor, Mike Dustin |
PI: Dr Joanna Hester & Dr Fadi Issa |
|
|
|
|
'Ultra low-dose IL-2 therapy in autoimmune diabetes' |
'Use of unbiased T-cell receptor repertoire sequencing to identify novel T-cell subsets involved in coeliac disease and increase the accuracy of the diagnosis of gluten sensitivity' |
'Investigation of T cell reactivity to alpha-synuclein in Parkinson's disease' |
|
PI: John Todd, Claudia Monaco |
PI: Elizabeth Soilleux, Paul Klennerman |
|
|
|
|
|
'Determining changes in clonal/sub clonal architecture and relation to immune marrow environment enabling tumour persistence/relapse in myeloma' |
'Defining an early signature of neutrophil extracellular trap formative predictive of responses to PAD4/2 inhibitors in rheumatic patients' |
'Checkpoint blockade-mediated autoimmune colitis as a model for gut immune homeostasis' |
| PI: Paresh Vyas, Udo Oppermann, Karthik Ramasamy | PI: Irina Udalova, Raashid Luqman | PI: Paul Klenerman, Oliver Brain |
Past Fellows
|
|
|
|
'Definition of new drug targets for fibrosis in Crohns' |
'Single cell analysis of the fibrotic landscape in Dupuytren's Disease' |
'Unravelling the role of E2F-1 citrullination in inflammatory disease' |
|
PI: Alison Simmons |
PI: Jagdeep Nanchahal |
PI: Nick La Thangue |
|
|
|
|
|
||
|
'Clonal and Functional heterogeneity in AG221-treated IDH2 mutant Acute Myeloid Leukaemia' |
|
|
|
PI: Paresh Vyas |
|
|